HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): James S. Gammie Marco Zenati Robert L. Kormos Brack G. Hattler Lawrence M. Wei Ronald V. Pellegrini Bartley P. Griffith Cornelius M. Dyke Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gammie, J. S. Articles by Dyke, C. M. Search for Related Content PubMed PubMed Citation Articles by Gammie, J. S. Articles by Dyke, C. M.

Ann Thorac Surg 1998;65:465-469
© 1998 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Abciximab and Excessive Bleeding in Patients Undergoing Emergency Cardiac Operations

Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

Accepted for publication August 15, 1997.

Dr Gammie, Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Suite C-700 Scaife, 200 Lothrop St, Pittsburgh, PA 15213 (e-mail: gam@med.pitt.edu).

Background. Abciximab (ReoPro; Eli Lilly and Co, Indianapolis, IN) is a monoclonal antibody that binds to the platelet glycoprotein IIb/IIIa receptor and produces powerful inhibition of platelet function. Clinical trials of abciximab in patients undergoing coronary angioplasty have demonstrated a reduction in thrombotic complications and have encouraged the widespread use of this agent. We have observed a substantial incidence of excessive bleeding among patients who receive abciximab and subsequently require emergency cardiac operations.

Methods. The records of 11 consecutive patients who required emergency cardiac operations after administration of abciximab and failed angioplasty or stent placement were reviewed.

Results. The interval from the cessation of abciximab administration to operation was critical in determining the degree of coagulopathy after cardiopulmonary bypass. The median values for postoperative chest drainage (1,300 versus 400 mL; p < 0.01), packed red blood cells transfused (6 versus 0 U; p = 0.02), platelets transfused (20 versus 0 packs; p = 0.02), and maximum activated clotting time (800 versus 528 seconds; p = 0.01) all were significantly greater in the early group (cardiac operation <12 hours after abciximab administration; n = 6) compared with the late (cardiac operation >12 hours after abciximab administration; n = 5) group.

Conclusions. This report suggests that the antiplatelet agent abciximab is associated with substantial bleeding when it is administered within 12 hours of operation.

This article has been cited by other articles:

				M. Makar, J. Taylor, M. Zhao, A. Farrohi, M. Trimming, and N. D'Attellis Perioperative Coagulopathy, Bleeding, and Hemostasis During Cardiac Surgery: A Comprehensive Review ICU Director, January 1, 2010; 1(1): 17 - 27. [Abstract] [PDF]

				J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell Antiplatelet Agents in the Perioperative Period Arch Surg, January 1, 2009; 144(1): 69 - 76. [Abstract] [Full Text] [PDF]

				C. M. Dyke, L. K. Jennings, G. Maier, C. Andreou, R. Daly, and M. R. Tamberella III Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 54 - 60. [Abstract] [PDF]

				M. A. Tucci, M. T. Ganter, C. R. Hamiel, R. Klaghofer, A. Zollinger, and C. K. Hofer Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1314 - 1322. [Abstract] [Full Text] [PDF]

				R. I. Aviv, R. O'Neill, M. C. Patel, and I. R. Colquhoun Abciximab in Patients with Ruptured Intracranial Aneurysms AJNR Am. J. Neuroradiol., August 1, 2005; 26(7): 1744 - 1750. [Abstract] [Full Text] [PDF]

				A. Shander, D. Moskowitz, and T. S. Rijhwani The Safety and Efficacy of "Bloodless" Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 53 - 63. [Abstract] [PDF]

				N. Katori, F. Szlam, J. H. Levy, and K. A. Tanaka A Novel Method to Assess Platelet Inhibition by Eptifibatide with Thrombelastograph(R) Anesth. Analg., December 1, 2004; 99(6): 1794 - 1799. [Abstract] [Full Text] [PDF]

				M. W.A. Chu, S. R. Wilson, R. J. Novick, L. W. Stitt, and M. A. Quantz Does Clopidogrel Increase Blood Loss Following Coronary Artery Bypass Surgery? Ann. Thorac. Surg., November 1, 2004; 78(5): 1536 - 1541. [Abstract] [Full Text] [PDF]

				J. K. Song, Y. Niimi, P. M. Fernandez, J. L. Brisman, R. Buciuc, M. J. Kupersmith, and A. Berenstein Thrombus Formation during Intracranial Aneurysm Coil Placement: Treatment with Intra-Arterial Abciximab AJNR Am. J. Neuroradiol., August 1, 2004; 25(7): 1147 - 1153. [Abstract] [Full Text] [PDF]

				D. M. Moskowitz, J. J. Klein, A. Shander, K. M. Cousineau, R. S. Goldweit, C. Bodian, S. I. Perelman, H. Kang, D. A. Fink, H. C. Rothman, et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center Ann. Thorac. Surg., February 1, 2004; 77(2): 626 - 634. [Abstract] [Full Text] [PDF]

				S. Pothula, V. T. Sanchala, B. Nagappala, and M. A. Inchiosa Jr. The Effect of Preoperative Antiplatelet/Anticoagulant Prophylaxis on Postoperative Blood Loss in Cardiac Surgery Anesth. Analg., January 1, 2004; 98(1): 4 - 10. [Abstract] [Full Text] [PDF]

				E. H. Kincaid, M. L. Monroe, D. L. Saliba, N. D. Kon, W. G. Byerly, and M. G. Reichert Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting Ann. Thorac. Surg., July 1, 2003; 76(1): 124 - 128. [Abstract] [Full Text] [PDF]

				R. Chun, B. A. Orser, and M. Madan Platelet Glycoprotein IIb/IIIa Inhibitors: Overview and Implications for the Anesthesiologist Anesth. Analg., October 1, 2002; 95(4): 879 - 888. [Full Text] [PDF]

				T. Kovesi and D. Royston Editorial I: Is there a bleeding problem with platelet-active drugs? Br. J. Anaesth., February 1, 2002; 88(2): 159 - 163. [Full Text] [PDF]

				L. Y Lee, W. DeBois, K. H Krieger, L. N Girardi, L. Russo, J. McVey, W. Ko, N. K Altorki, R. A Brodman, and O W. Isom The effects of platelet inhibitors on blood use in cardiac surgery Perfusion, January 1, 2002; 17(1): 33 - 37. [Abstract] [PDF]

				G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]

				J. H. Waters, D. G. Anthony, A. Gottlieb, and J. Sprung Bleeding in a Patient Receiving Platelet Aggregation Inhibitors Anesth. Analg., October 1, 2001; 93(4): 878 - 882. [Abstract] [Full Text] [PDF]

				N. J. Skubas and G. J. Despotis Optimal Management of Bleeding Complications After Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 217 - 228. [Abstract] [PDF]

				M. Genoni, D. Zeller, O. Bertel, M. Maloigne, and M. Turina Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 630 - 632. [Full Text] [PDF]

				C. S. Roberts and N. R. Bocanegra Emergent operation for percutaneous coronary rupture after abciximab administration Ann. Thorac. Surg., June 1, 2001; 71(6): 2024 - 2026. [Abstract] [Full Text] [PDF]

				C. M. Dyke, D. Bhatia, T. J. Lorenz, S. P. Marso, B. E. Tardiff, C. Hogeboom, and R. A. Harrington Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT Ann. Thorac. Surg., September 1, 2000; 70(3): 866 - 871. [Abstract] [Full Text] [PDF]

				A. M. Lincoff, L. A. LeNarz, G. J. Despotis, P. K. Smith, J. E. Booth, R. E. Raymond, S. K. Sapp, C. F. Cabot, J. E. Tcheng, R. M. Califf, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials Ann. Thorac. Surg., August 1, 2000; 70(2): 516 - 526. [Abstract] [Full Text] [PDF]

				J. H. Levy Platelet inhibitors and bleeding in cardiac surgical patients Ann. Thorac. Surg., August 1, 2000; 70(2): S9 - 11. [Abstract] [Full Text] [PDF]

				S. C. Silvestry and P. K. Smith Current status of cardiac surgery in the abciximab-treated patient Ann. Thorac. Surg., August 1, 2000; 70(2): S12 - 19. [Abstract] [Full Text] [PDF]

				G. J. Despotis and L. T. Goodnough Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32. [Abstract] [Full Text] [PDF]

				J. H. Lemmer Jr Clinical experience in coronary bypass surgery for abciximab-treated patients Ann. Thorac. Surg., August 1, 2000; 70(2): S33 - 37. [Abstract] [Full Text] [PDF]

				S. R. Steinhubl, S. A. Moore, and A. M. Lincoff Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 401 - 401. [Full Text]

				J. H. Lemmer Jr, M. T. Metzdorff, A. H. Krause Jr, M. A. Martin, J. E. Okies, and J. G. Hill Emergency coronary artery bypass graft surgery in abciximab-treated patients Ann. Thorac. Surg., January 1, 2000; 69(1): 90 - 95. [Abstract] [Full Text] [PDF]

				R. M. Scarborough, N. S. Kleiman, and D. R. Phillips Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, July 27, 1999; 100(4): 437 - 444. [Abstract] [Full Text] [PDF]

				M. Poullis, R. Manning, D. Haskard, and K. Taylor REOPRO REMOVAL DURING CARDIOPULMONARY BYPASS USING A HEMOCONCENTRATOR J. Thorac. Cardiovasc. Surg., May 1, 1999; 117(5): 1032 - 1034. [Full Text] [PDF]

				T. E. Lempert, A. M. Malek, V. V. Halbach, C. C. Phatouros, C. F. Dowd, and R. T. Higashida Rescue Treatment of Acute Parent Vessel Thrombosis With Glycoprotein IIb/IIIa Inhibitor During GDC Coil Embolization Stroke, March 1, 1999; 30 (3): 693 - 695. [Full Text] [PDF]

				H. Arjomand, D. A.N. Mascarenhas, and R. J. Morgan Abciximab and the risk of bleeding during emergency cardiac operations Ann. Thorac. Surg., January 1, 1999; 67(1): 292 - 293. [Full Text] [PDF]

				C. Dyke and J. S. Gammie Surgical implications of platelet glycoprotein IIb-IIIa inhibition J. Thorac. Cardiovasc. Surg., December 1, 1998; 116(6): 1083 - 1084. [Full Text]